Systematic Review Article

载脂蛋白A-1作为实体瘤的潜在生物标志物:系统评价和荟萃分析

卷 30, 期 29, 2023

发表于: 22 March, 2023

页: [3356 - 3367] 页: 12

弟呕挨: 10.2174/0929867330666230210112700

价格: $65

Open Access Journals Promotions 2
摘要

背景:多项研究报道了载脂蛋白 A-I(ApoA-I)作为不同恶性肿瘤标志物的诊断价值;然而,结果却自相矛盾。目前的荟萃分析检查了 ApoA-I 水平与人类恶性肿瘤之间的关联。 方法:我们审查了数据库并检索了截至 2021 年 11 月 1 日的论文进行分析。进行了随机效应荟萃分析以构建汇总诊断参数。为了找到异质性的原因,我们使用了 Spearman 阈值效应分析和亚组分析。 I2 和卡方检验用于检查异质性。此外,还根据样本类型(血清/尿液)和研究的地理区域进行了亚组分析。最后,使用 Begg 和 Egger 的测试探索了发表偏倚。 结果:共纳入 11 篇文章,涉及 4,121 名参与者(2,430 名病例和 1,691 名对照)。总体汇总敏感性、特异性、阳性似然比 (PLR)、阴性似然比 (NLR)、诊断优势比 (DOR) 和曲线下面积 (AUC) 分别为 0.764(95% CI:0.746 - 0.781)、0.795( 95% CI:0.775 - 0.814)、5.105(95% CI:3.313 - 7.865)、0.251(95% CI:0.174 - 0.364)、24.61(95% CI:12.22 - 49.54)和 0.93。在亚组分析中,发现尿样和东亚国家(中国、韩国和台湾)具有更好的诊断价值。 结论:尿液 ApoA-I 水平可作为癌症的有利诊断标志物。

关键词: 载脂蛋白A-I(ApoA-1),癌症,血清,尿液,诊断,生物标志物。

[1]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Hasan, M.; Ahommed, M.; Daizy, M.; Bacchu, M.; Ali, M.; Al-Mamun, M. Recent development in electrochemical biosensors for cancer biomarkers detection. Biosens. Bioelectron., 2021, X, 100075.
[3]
Bonatelli, M.; Fornari, I.F.; Bernécule, P.N.; Pinheiro, L.E.; Costa, R.F.A.; Longatto-Filho, A.; Junior, J.N.A.; Silva, E.C.A.; Cárcano, F.M.; Pinheiro, C. Expression of glycolysis-related proteins in cancer of unknown primary origin. Front. Oncol., 2021, 11, 682665.
[http://dx.doi.org/10.3389/fonc.2021.682665] [PMID: 34249728]
[4]
Jiang, R.; Yang, Z.H.; Luo, D.H.; Guo, L.; Sun, R.; Chen, Q.Y.; Huang, P.Y.; Qiu, F.; Zou, X.; Cao, K.J.; Mai, H.Q.; Guo, X.; Qian, C.N.; Hong, M.H.; Chen, M.Y. Elevated apolipoprotein A-I levels are associated with favorable prognosis in metastatic nasopharyngeal carcinoma. Med. Oncol., 2014, 31(8), 80.
[http://dx.doi.org/10.1007/s12032-014-0080-y] [PMID: 25023050]
[5]
Gao, F.; Vasquez, S.X.; Su, F.; Roberts, S.; Shah, N.; Grijalva, V.; Imaizumi, S.; Chattopadhyay, A.; Ganapathy, E.; Meriwether, D.; Johnston, B.; Anantharamaiah, G.M.; Navab, M.; Fogelman, A.M.; Reddy, S.T.; Farias-Eisner, R. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways. Integr. Biol., 2011, 3(4), 479-489.
[http://dx.doi.org/10.1039/c0ib00147c] [PMID: 21283904]
[6]
Magray, J.A.; Pandith, A.A.; Qasim, I.; Khateeb, M.; Hamid, A.; Koul, A.; Shah, Z.A.; Baba, S.M.; Mansoor, S.; Charifi, W.; Ahmad, A.; Wani, M.S. Significant implications of APOA1 gene sequence variations and its protein expression in bladder cancer. Biomedicines, 2021, 9(8), 938.
[http://dx.doi.org/10.3390/biomedicines9080938] [PMID: 34440141]
[7]
Kim, S.E.; Kim, Y.J.; Song, S.; Lee, K.N.; Seong, W.K. A simple electrochemical immunosensor platform for detection of Apolipoprotein A1 (Apo-A1) as a bladder cancer biomarker in urine. Sens. Actuators B Chem., 2019, 278, 103-109.
[http://dx.doi.org/10.1016/j.snb.2018.09.068]
[8]
Yelamanchili, D.; Liu, J.; Gotto, A.M., Jr; Hurley, A.E.; Lagor, W.R.; Gillard, B.K.; Davidson, W.S.; Pownall, H.J.; Rosales, C. Highly conserved amino acid residues in apolipoprotein A1 discordantly induce high density lipoprotein assembly in vitro and in vivo. Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 2020, 1865(12), 158794.
[http://dx.doi.org/10.1016/j.bbalip.2020.158794] [PMID: 32810603]
[9]
McInnes, M.D.F.; Moher, D.; Thombs, B.D.; McGrath, T.A.; Bossuyt, P.M.; Clifford, T.; Cohen, J.F.; Deeks, J.J.; Gatsonis, C.; Hooft, L.; Hunt, H.A.; Hyde, C.J.; Korevaar, D.A.; Leeflang, M.M.G.; Macaskill, P.; Reitsma, J.B.; Rodin, R.; Rutjes, A.W.S.; Salameh, J.P.; Stevens, A.; Takwoingi, Y.; Tonelli, M.; Weeks, L.; Whiting, P.; Willis, B.H. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA, 2018, 319(4), 388-396.
[http://dx.doi.org/10.1001/jama.2017.19163] [PMID: 29362800]
[10]
Okuda, M.; Kamiya, S.; Booka, M.; Kikuchi, S.; Osaki, T.; Hiwatani, T.; Maekawa, K.; Fukuda, Y. Diagnostic accuracy of urine-based kits for detection of Helicobacter pylori antibody in children. Pediatr. Int., 2013, 55(3), 337-341.
[http://dx.doi.org/10.1111/ped.12057] [PMID: 23360308]
[11]
Aalami, A.H.; Abdeahad, H.; Mesgari, M.; Sahebkar, A. MiRNA-223 in gastrointestinal cancers: A systematic review and diagnostic meta-analysis. Eur. J. Clin. Invest., 2021, 51(2), e13448.
[http://dx.doi.org/10.1111/eci.13448] [PMID: 33244751]
[12]
Gourin, C.G.; Zhi, W.; Adam, B.L. Proteomic identification of serum biomarkers for head and neck cancer surveillance. Laryngoscope, 2009, 119(7), 1291-1302.
[http://dx.doi.org/10.1002/lary.20279] [PMID: 19444892]
[13]
Mao, M.; Wang, X.; Sheng, H.; Liu, Y.; Zhang, L.; Dai, S.; Chi, P. A novel score based on serum apolipoprotein A-1 and C-reactive protein is a prognostic biomarker in hepatocellular carcinoma patients. BMC Cancer, 2018, 18(1), 1178.
[http://dx.doi.org/10.1186/s12885-018-5028-8] [PMID: 30486825]
[14]
Chang, Y-K.; Lai, Y-H.; Chu, Y.; Lee, M-C.; Huang, C-Y.; Wu, S. Haptoglobin is a serological biomarker for adenocarcinoma lung cancer by using the ProteomeLab PF2D combined with mass spectrometry. Am. J. Cancer Res., 2016, 6(8), 1828-1836.
[PMID: 27648369]
[15]
Shi, H.; Huang, H.; Pu, J.; Shi, D.; Ning, Y.; Dong, Y.; Han, Y.; Zarogoulidis, P.; Bai, C. Decreased pretherapy serum apolipoprotein A-I is associated with extent of metastasis and poor prognosis of non-small-cell lung cancer. OncoTargets Ther., 2018, 11, 6995-7003.
[http://dx.doi.org/10.2147/OTT.S170227] [PMID: 30410356]
[16]
Ehmann, M.; Felix, K.; Hartmann, D.; Schnölzer, M.; Nees, M.; Vorderwülbecke, S.; Bogumil, R.; Büchler, M.W.; Friess, H. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas, 2007, 34(2), 205-214.
[http://dx.doi.org/10.1097/01.mpa.0000250128.57026.b2] [PMID: 17312459]
[17]
Farias-Eisner, G.; Su, F.; Robbins, T.; Kotlerman, J.; Reddy, S.; Farias-Eisner, R. Validation of serum biomarkers for detection of early-and late-stage endometrial cancer. Am. J. Obstet. Gynecol., 2010, 202(1), 73, e1-e5.
[http://dx.doi.org/10.1016/j.ajog.2009.07.049]
[18]
Ahn, H.S.; Shin, Y.S.; Park, P.J.; Kang, K.N.; Kim, Y.; Lee, H-J.; Yang, H-K.; Kim, C.W. Serum biomarker panels for the diagnosis of gastric adenocarcinoma. Br. J. Cancer, 2012, 106(4), 733-739.
[http://dx.doi.org/10.1038/bjc.2011.592] [PMID: 22240791]
[19]
Salem, H.; Ellakwa, D.E.S.; Fouad, H.; Hamid, M.A. APOA1 AND APOA2 proteins as prognostic markers for early detection of urinary bladder cancer. Gene Rep., 2019, 16, 100463.
[http://dx.doi.org/10.1016/j.genrep.2019.100463]
[20]
Li, H.; Li, C.; Wu, H.; Zhang, T.; Wang, J.; Wang, S.; Chang, J. Identification of Apo-A1 as a biomarker for early diagnosis of bladder transitional cell carcinoma. Proteome Sci., 2011, 9(1), 21.
[http://dx.doi.org/10.1186/1477-5956-9-21] [PMID: 21496341]
[21]
Li, C.; Li, H.; Zhang, T.; Li, J.; Liu, L.; Chang, J. Discovery of Apo-A1 as a potential bladder cancer biomarker by urine proteomics and analysis. Biochem. Biophys. Res. Commun., 2014, 446(4), 1047-1052.
[http://dx.doi.org/10.1016/j.bbrc.2014.03.053] [PMID: 24661883]
[22]
Chen, Y.T.; Chen, C.L.; Chen, H.W.; Chung, T.; Wu, C.C.; Chen, C.D.; Hsu, C.W.; Chen, M.C.; Tsui, K.H.; Chang, P.L.; Chang, Y.S.; Yu, J.S. Discovery of novel bladder cancer biomarkers by comparative urine proteomics using iTRAQ technology. J. Proteome Res., 2010, 9(11), 5803-5815.
[http://dx.doi.org/10.1021/pr100576x] [PMID: 20806971]
[23]
Zhu, Y.M.; Verma, S.; Fung, M.; McQueen, M.J.; Anderson, T.J.; Lonn, E.M. Association of apolipoproteins B and A-1 with markers of vascular health or cardiovascular events. Can. J. Cardiol., 2017, 33(10), 1305-1311.
[http://dx.doi.org/10.1016/j.cjca.2017.08.004] [PMID: 28941609]
[24]
Yao, X.; Gordon, E.M.; Figueroa, D.M.; Barochia, A.V.; Levine, S.J. Emerging roles of apolipoprotein E and apolipoprotein AI in the pathogenesis and treatment of lung disease. Am. J. Respir. Cell Mol. Biol., 2016, 55(2), 159-169.
[http://dx.doi.org/10.1165/rcmb.2016-0060TR] [PMID: 27073971]
[25]
Gorabi, A.M.; Kiaie, N.; Khosrojerdi, A.; Jamialahmadi, T.; Al-Rasadi, K.; Johnston, T.P. Implications for the role of lipopolysaccharide in the development of atherosclerosis. Trends Cardiovasc. Med., 2021, 32(8), 525-533.
[PMID: 34492295]
[26]
Zhao, T.J.; Zhu, N.; Shi, Y.N.; Wang, Y.X.; Zhang, C.J.; Deng, C.F.; Liao, D.F.; Qin, L. Targeting HDL in tumor microenvironment: New hope for cancer therapy. J. Cell. Physiol., 2021, 236(11), 7853-7873.
[http://dx.doi.org/10.1002/jcp.30412] [PMID: 34018609]
[27]
Gkouskou, K.K.; Ioannou, M.; Pavlopoulos, G.A.; Georgila, K.; Siganou, A.; Nikolaidis, G.; Kanellis, D.C.; Moore, S.; Papadakis, K.A.; Kardassis, D.; Iliopoulos, I.; McDyer, F.A.; Drakos, E.; Eliopoulos, A.G. Apolipoprotein A-I inhibits experimental colitis and colitis-propelled carcinogenesis. Oncogene, 2016, 35(19), 2496-2505.
[http://dx.doi.org/10.1038/onc.2015.307] [PMID: 26279300]
[28]
Kim, K.; Kim, M.J.; Kim, K.H.; Ahn, S.A.; Kim, J.H.; Cho, J.Y.; Yeo, S.G. C1QBP is upregulated in colon cancer and binds to apolipoprotein A-I. Exp. Ther. Med., 2017, 13(5), 2493-2500.
[http://dx.doi.org/10.3892/etm.2017.4249] [PMID: 28565870]
[29]
Georgila, K.; Gounis, M.; Havaki, S.; Gorgoulis, V.G.; Eliopoulos, A.G. mTORC1-dependent protein synthesis and autophagy uncouple in the regulation of Apolipoprotein A-I expression. Metabolism, 2020, 105, 154186.
[http://dx.doi.org/10.1016/j.metabol.2020.154186] [PMID: 32084429]
[30]
O’Sullivan, P.; Sharples, K.; Dalphin, M.; Davidson, P.; Gilling, P.; Cambridge, L.; Harvey, J.; Toro, T.; Giles, N.; Luxmanan, C.; Alves, C.F.; Yoon, H.S.; Hinder, V.; Masters, J.; Kennedy-Smith, A.; Beaven, T.; Guilford, P.J. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J. Urol., 2012, 188(3), 741-747.
[http://dx.doi.org/10.1016/j.juro.2012.05.003] [PMID: 22818138]
[31]
Batista, R.; Vinagre, N.; Meireles, S.; Vinagre, J.; Prazeres, H.; Leão, R.; Máximo, V.; Soares, P. Biomarkers for bladder cancer diagnosis and surveillance: A comprehensive review. Diagnostics (Basel), 2020, 10(1), 39.
[http://dx.doi.org/10.3390/diagnostics10010039] [PMID: 31941070]
[32]
Liu, X.; Zheng, W.; Wang, W.; Shen, H.; Liu, L.; Lou, W.; Wang, X.; Yang, P. A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline. Br. J. Cancer, 2017, 117(12), 1846-1854.
[http://dx.doi.org/10.1038/bjc.2017.365] [PMID: 29123261]
[33]
Kozak, K.R.; Su, F.; Whitelegge, J.P.; Faull, K.; Reddy, S.; Farias-Eisner, R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics, 2005, 5(17), 4589-4596.
[http://dx.doi.org/10.1002/pmic.200500093] [PMID: 16237736]
[34]
Ai, J.; Tan, Y.; Ying, W.; Hong, Y.; Liu, S.; Wu, M.; Qian, X.; Wang, H. Proteome analysis of hepatocellular carcinoma by laser capture microdissection. Proteomics, 2006, 6(2), 538-546.
[http://dx.doi.org/10.1002/pmic.200500257] [PMID: 16342242]
[35]
Zhang, Y.; Yang, X. Prognostic significance of pretreatment apolipoprotein AI as a noninvasive biomarker in cancer survivors: A meta-analysis. Disease Markers, 2018, 2018, 1034037.
[36]
Wu, J.; Zhang, C.; Zhang, G.; Wang, Y.; Zhang, Z.; Su, W.; Lyu, J. Association between pretreatment serum apolipoprotein A1 and prognosis of solid tumors in Chinese population: A systematic review and meta-analysis. Cell. Physiol. Biochem., 2018, 51(2), 575-588.
[http://dx.doi.org/10.1159/000495277] [PMID: 30466099]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy